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Abstract
Background: Secondary prevention plays an important role after acute coronary event due to high 
risk of adverse events in elderly. In present study we aimed to evaluate the lifestyle, management of risk 
factors and medical treatment for secondary protection in elderly patients with known coronary heart 
disease (CHD).
Methods: ELDERTURK is a non-interventional, multi-centered, observational study, which included 
total of 5694 elderly patients (> 65 years) from 50 centers in Turkey. In this study elderly patients from 
the ELDERTURK population with known CHD were evaluated for cardiovascular risk factors, comor-
bidities and medication usage.
Results: A total of 2976 (52.3% of study) out of 5694 patients included in the ELDERTURK study 
were evaluated. All had known CHD with a mean age of 73.4 ± 6.2 years and 60.3% were male. 
13.0% of patients were smokers, 42.4% were overweight and 21.1% were obese. Only 23.6% of patients 
reported to do regular exercise, 73.4% had history of hypertension, 47.4% had dyslipidemia and 33.9% 
had diabetes mellitus. The rate of patients with systolic blood pressure > 140 mmHg were 31.1% and 
only 13.9% of patients had a recommended ≤ 70 mg/dL level of low-density lipoprotein cholesterol. Anti-
platelet, statin, beta-blocker and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker 
usage was limited to 27.3%.
Conclusions: The ELDERTURK study shows that many patients with CHD have a high prevalence of 
modifiable risk factors and unhealthy lifestyle. Apart from this, many patients are not receiving thera-
peutic intervention and as a consequence most were not achieving the recommended goals. (Cardiol J 
2019; 26, 1: 13–19)
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Introduction
The elderly population is rapidly increasing in 
Turkey as in all industrialized countries. The rate of 
population aged ≥ 65 is expected to reach 10.2% in 
2023, 20.8% in 2050 [1]. In several studies, increas-
ing age is a powerful predictor of both short-term 
and long-term mortality following acute myocardial 
infarction [2–4]. The prevalence and incidence of 
coronary heart diseases (CHD) are significantly in-
creased in the elderly population due to increase of 
traditional risk factors and prevalence which is asso-
ciated with aging due to increases of inflammation, 
endothelial dysfunction and atherosclerosis [3]. 
The presence of obstructive coronary artery dis-
ease at autopsy is 50% in elderly women and 70% 
to 80% in elderly men [5]. Secondary prevention 
is as important as acute treatment in patients 
with CHD. There is clear guidance for secondary 
protection with lifestyle changes, management of 
risk factors and appropriate drug therapy advice. 
However, guideline recommendations may not 
apply exactly in practical living. Especially recom-
mendations which could be applied less in elderly 
patients due to polypharmacy, drug interactions and 
side effect concerns associated with difficulties in 
changing long-term habits [6].
In the present study the aim was to evaluate 
lifestyle, management of risk factors and medical 
treatment for secondary prevention in elderly 
patients with known CHD enrolled in the ELDER-
TURK study.
Methods
The design, conduct, and main results of the 
ELDERTURK (Frequency of cardiovascular disea-
ses and drug use in the elderly Turkish population 
was followed up at cardiology clinics) in this study 
have been presented previously [7]. In brief, the 
ELDERTURK study was a non-interventional, 
multi-centered, observational study to provide 
national epidemiological data for the incidence 
of cardiovascular diseases, risk factors, comorbid 
diseases and drug usage among an elderly group 
(> 65 years of age) in Turkey. This study was 
performed with the Institutional Review Board 
protocol approval date 11/03/2015 and number 
700 between March 2015 and December 2015. All 
patients 65 years and older who admitted to the 
inpatient and outpatient cardiology clinics with 
symptoms were enrolled in the study. 
Study inclusion criteria were as follows:
 — 65 years and older age;
 — admitted to an outpatient clinic and were able 
to provide a medical history;
 — gave written consent.
Study exclusion criteria were as followed:
 — below 65 years old;
 — not available to give a reliable medical history 
because of concomitant diseases;
 — refusal to give written consent.
A total of 5694 patients from 73 centers around 
different parts of Turkey were included. In this 
study elderly patients from the ELDERTURK 
population with known CHD (n = 2976; 52.3% of 
study) were included to evaluate cardiovascular 
risk factors, comorbidities and medication usage. 
CHD was defined as having a previous history of 
a coronary artery bypass graft (CABG) operation, 
percutaneous trans-luminal coronary angioplasty 
or stent, myocardial infarction, and stable coro-
nary artery disease. Demographic information of 
the patients were recorded. The smoking habit 
was described as being an active smoker defined 
inclusion to the study. Participants who exercised 
were grouped as doing exercise less than 150 min 
or more than this per week. Patients who were 
newly diagnosed with diabetes mellitus (DM) or 
were already on anti-diabetic therapy were iden-
tified as diabetic. Hypertension was defined as 
taking anti-hypertensive therapy, diagnosed with 
hypertension or having a systolic blood pressure 
(SBP) ≥ 140 mmHg and diastolic blood pressure 
(DBP) ≥ 90 mmHg without diagnosis. The value of 
SBP < 140 mmHg was the target value for blood 
pressure control as recommended by European So-
ciety of Cardiology (ESC) hypertension guidelines 
in patients with CHD [8]. Body mass index (BMI) 
was calculated by using weight [kg]/height [m2] 
formula. Subjects were divided into four groups 
based on BMI: underweight < 18.5 kg/m2; normal 
18.5–24.9 kg/m2; overweight 25–29.9 kg/m2 and 
obese ≥ 30 kg/m2 [9]. Total cholesterol, low-density 
lipoprotein cholesterol (LDL-C), high-density li-
poprotein cholesterol (HDL-C), triglyceride and 
fasting blood glucose levels were recorded for each 
patient. Target values recommended by the ESC 
dyslipidemia guideline is LDL-C ≤ 70 mg/dL or 
a ≥ 50% reduction from baseline LDL-C in patients 
with known CHD [10]. In this study target LDL-C 
level was < 70 mg/dL.
Statistical analysis 
All  data were analyzed with SPSS (Statisti-
cal Package for the Social Sciences) software for 
Windows version 20.0. Continuous and quantitative 
data were summarized using descriptive statistics 
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including mean, standard deviations, medians 
(min–max), frequency distributions and percent-
ages. Normality of data distribution was verified 
by Kolmogorov-Smirnov/Shapiro-Wilk test. Ho-
mogeneity of variance was assessed by Levene’s 
test. Quantitative variables were compared with 
Student t test or Mann-Whitney U test. P-values 
of < 0.05 were considered statistically significant.
Results
Among 2976 patients with CHD, 60.3% were 
male, mean age was 73.4 ± 6.2 (65–94) years and 
18.2% of patients (n = 541) were > 80 years old. 
Characteristic features of the patients are summa-
rized in Table 1. 43.3% (n = 1290) of patients had 
a history of percutaneous transluminal coronary 
angioplasty/stent and 28.1% (n = 837) CABG. The 
number of patients diagnosed with heart failure was 
1128 (37.9%) and heart failure with reduced ejec-
tion fraction (22.9 %, n = 681) was more frequent. 
Patients who had a history of arrhythmia were 
reported at 27.2% (n = 810) and the most frequent 
arrhythmia was atrial fibrillation/flutter (80%, 
n = 649). 13.0% (n = 387) of patients were smok-
ers and the ratio of male smokers (19%, n = 334) 
was significantly higher than in the female smokers 
(4.5%, n = 53) (p < 0.001). Hypertension (73.4%, 
n = 2184) was the most frequent risk factor fol-
lowed by hyperlipidemia (47.4%, n = 1412) and 
diabetes mellitus (33.9%, n = 1008). The mean 
BMI was 27.6 ± 4.4 kg/m2 (median 27.2, 14.6–58.8) 
and 42.4% (n = 1261) were overweight and 21.1% 
(n = 628) were obese (Table 2). Seven hundred 
and four (n = 704, 23.6%) patients reported that 
they did regular exercise, but only a limited 11.7% 
(n = 347) exercised more than 150 min or more 
per week. Median systolic and diastolic blood 
pressures were 130 (70–220) and 80 (25–122), 
respectively in patients whose blood pressures 
were recorded (n = 2636, 88.5% of study popula-
tion). The rate of patients with SBP > 140 mmHg 
were 31.1% (n = 819) among patients whose blood 
pressure was recorded (Table 2).
Additionally, among patients who had hyper-
tension (n = 2184, 73.4% of study population) the 
rate of patients with SBP > 140 mmHg were re-
Table 1. Baseline characteristic features of  
patients.
Features N Mean ± SD 
or %
Age [years] 2976 73.4 ± 6.2
≥ 80 years 541 18.2
Male 1794 60.3
CABG 837 28.1
PTCA/stent 1290 43.3
Heart failure 1128 37.9
HFrEF 681 22.9
HFpEF 447 15.0
Dysrhythmia 810 27.2
Pacemaker 116 3.9
Prosthetic valve 91 3.1
Cigarette smoking 388 13.0
Exerciser 704 23.6
Exercise < 150 min/week 357 12.0
Exerciser > 150 min/week 347 11.7
Hypertension 2184 73.4
Hyperlipidemia 1412 47.4
Diabetes mellitus 1008 33.9
Anemia 508 17.1
Pulmonary hypertension: 508 17.1
Primary 8 0.3
Secondary 500 16.8
Respiratory system disease 596 20.0
CABG — coronary artery bypass graft; HFrEF — heart failure with 
reduced ejection fraction; HFpEF — heart failure with preserved 
ejection fraction; PTCA — percutaneous transluminal coronary  
angioplasty; SD — standard deviation
Table 2. Laboratory values of study population.
Feature Median  
(min.–max.)
BMI [kg/m2] 27.2 (14.6–58.8)
Overweight (BMI 25–29.9 kg/ m2)  
(n = 1261)
42.4%
Obese (BMI ≥ 30 kg/m2) (n = 628) 21.1%
SBP [mmHg] (n = 2636) 130 (70–220)
DBP [mmHg] (n = 2636) 80 (25–122)
SBP > 140 mmHg (n = 819) 31.1%
Heart rate [bpm] 75 (32–169)
Hemoglobin 13 (7–19)
eGFR 67.2 (1–176)
Fasting blood glucose [mg/dL]  
(n = 2158)
105 (35–502)
Total cholesterol (n = 2203) 181 (76–514)
LDL-C (n = 2288) 106 (10–422)
LDL-C < 70 mg/dL (n = 318) 13.9%
Triglycerides [mg/dL] (n = 2275) 132 (27–906)
LDL-C < 70 mg/dL,  
SBP < 140 mmHg (n = 219)
9.6%
BMI — body mass index; DBP — diastolic blood pressure; eGFR — 
estimated glomerular filtration rate; LDC-C — low density lipopro-
tein cholesterol; SBP — systolic blood pressure
www.cardiologyjournal.org 15
Salih Kilic et al., Secondary prevention of coronary heart disease in elderly
ported as 33.9% (n = 739) and almost all (n = 716, 
98.1%) were receiving at least one anti-hyper-
tensive agent. Similarly, the rate of hypertensive 
patients with at least one antihypertensive therapy 
was high at 97.5% (n = 2129). The median LDL-C 
value was 106 (10–422) mg/dL in patients whose 
LDL-C was recorded (2288 patients; 76.9%). Only 
13.9% (n = 318) of patients had a LDL-C value 
of recommended ≤ 70 mg/dL level (Table 2). The 
recommendation level was reached in only 15.2% 
(n = 165) of patients with known hyperlipidemia 
similar to the entire population. Median LDL-C 
level was higher in patients with hyperlipidemia 
than non-hyperlipidemia or unknown patients 
(108 [30–422] mg/dL, 105 [10–281]; p = 0.002, 
respectively). The rate of statin use was 81.5% 
(n = 1151) in patients with  a history hyperlipi-
demia and 49.9% (n = 1485) in all patients. The 
rate of patients who met the recommendations of 
secondary prevention guidelines regarding both 
LDL-C level and SBP were  9.6% (n = 219). The 
rate of medication use in patients with known 
CHD are summarized in Table 3. 79.3% of patients 
(n = 2360) were on anti-platelet treatment (Table 4). 
Approximately half of patients who were on anti-
platelet treatment had concomitant use of proton 
pump inhibitors (PPI). This rate was slightly higher 
in patients who were receiving dual anti-platelet 
treatment. Concomitant use of anti-platelet and sta-
tin was limited to 44.7% (n = 1331) and combined 
anti-platelet, statin, beta-blocker usage was 35.1% 
(n = 1045) anti-platelet, statin, beta-blocker and 
angiotensin-converting enzyme inhibitor/angioten-
sin receptor blocker (ACEI/ARB) combination was 
used in 27.3% (n = 812).
Discussion
The assessment of elderly patients with CHD 
from the national epidemiologic study ELDER-
TURK has shown that most patients had hyper-
tension, half had hyperlipidemia and one-third had 
DM. Almost half of the patients were overweight 
and one fifth of all patients were obese andonly 
one-quarter of patients did regular exercise. The 
number of patients with target SBP reduction and 
LDL-C reduction was low,  elderly patients with 
known CHD  were far from receiving appropriate 
secondary prevention. 
The purpose of secondary prevention is to 
protect patients from major clinical events such 
as myocardial infarction and to reduce the progres-
sion of coronary heart disease. As in all developed 
economies the importance of secondary prevention 
in cardiovascular disease, which is increasing in 
Turkey and as well as in other elderly populations. 
In recent years, several randomized controlled 
studies, which demonstrate the importance of 
hypertension, hyperlipidemia, smoking, DM and 
antithrombotic treatment, have been published in 
secondary protection. Though it has been observed 
that a large part of elderly populations do not re-
ceive proven treatments in clinical practice [6].
Smoking is one of the major preventable risk 
factors for death [11, 12]. The EURIKA study in 
the Turkey group had an active smoking rate of 
23.7%, was close to 21.3% which is Europe’s av-
erage rate [13]. The EUROASPIRE II study has 
been shown that at the time of the index event 
87.7% of patient were smoking and at the inter-
view 21% of patients continued to smoke [14]. In 
Table 4. Distribution of anti-platelet therapy.
Medication N %
Acetylsalicylic acid 1501 63.6
Clopidogrel 290 12.2
Acetylsalicylic acid: clopidogrel 506 21.4
Acetylsalicylic acid: ticagrelor 48 2.0
Acetylsalicylic acid: prasugrel 5 0.2
Prasugrel 3 0.1
Ticagrelor 7 0.3
Total 2360 100
Table 3. Pharmacological treatment.
Drug treatment N = 2976 %
Anti-platelet 2360 79.3
Anti-platelet-PPI 1120 37.6
DAPT 559 18.8
DAPT-PPI 336 11.3
Anticoagulant 473 15.9
Statin 1485 49.9
Beta-blocker 2106 70.8
ACEI/ARB 2026 68.1
PPI 1368 46.0
Anti-platelet–statin 1331 44.7
Anti-platelet–statin–beta-
-blocker
1045 35.1
Anti-platelet–statin–beta- 
-blocker–ACE/ARB
812 27.3
ACEI — angiotensin-converting enzyme inhibitor; ARB —  
angiotensin receptor blocker; DAPT — dual anti-platelet  
treatment; PPI — proton pump inhibitor
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EUROASPIRE III study during index event 69.7% 
of all patients included and 73.1% of patients from 
Turkey were smokers [15]. Interviews after the 
index event, 23% of patients from Turkey and 17% 
of all patients continued smoking [16]. In the pre-
sent study smoking rates were lower compared to 
EUROASPIRE II, III and EURIKA studies. This 
could be explained by patients age differences in-
cluded in this study and by older patients who smoked 
less than younger patients. In the EUROASPIRE II 
44% of patients were over 60 years old, this rate 
was 58.6% in the EUROASPIRE III study.
A sedentary life is the main cause of many 
chronic diseases, CHD being one of the first. Simi-
larly, an increase in physical activity, independent 
from age, gender and ethnicity increases  quality 
of life [17]. Though, the rate of regular exercise 
among older patients is known to be very low [11]. 
In the EUROASPIRE III study, 59.1% of patients 
in the Europe group and 48.6% of patients in the 
Turkey group increased physical exercise, but only 
7.4% of the Turkish group reported intense physi-
cal activity (3–4 times a week for at least 20 min) 
[16]. Inthe present study results are similar to the 
EUROASPIRE III study. It is believed that the 
reason for the major part of the patients not doing 
physical activity or only light physical activity is 
due to being old and having comorbidities. Over-
weight, one of the major problems of the modern 
world is one of the leading causes of CHD. In the 
EURIKA study the obesity rate of the Turkish 
group was 36.2% and 43.5% for all patients included 
[13]. This study shows that even after a serious 
event like CHD, life style changes such as regular 
exercise and losing weight is not easily achieved. 
Hypertension is a risk factor that could affect 
all age groups as well as the elderly. Elderly popu-
lations have a high rate of hypertension and the 
Framingham study showed that lifelong risk is 90% 
[2, 18, 19]. In the EURIKA study, rate of hyper-
tension was 66.5% in the Turkey group, whereas 
it was 72.7% in the whole study group. Ninety-
four percent of all patients were under treatment 
for hypertension and only 38.8% reached target 
blood pressure levels [13]. In EUROASPIRE II, 
EUROASPIRE III and EUROASPIRE III the Tur-
key group, rate of patients with hypertension was 
89.9%, 81.4% and 75.2%, respectively and after the 
index event. Interviews showed that 50%, 56% and 
55.2% respectively did not reach target blood pres-
sure levels [14–16]. In the present study the rate 
of hypertension is similar to that of other studies. 
However, the rate of patients that achieved target 
blood pressure level were higher than in previous 
studies. The reason for high rates of target blood 
pressure level achievement may be due to regular 
medical treatment and frequent follow-up. 
The relationship between LDL-C level and 
cardiovascular events continue in  elderly people, 
despite a reduction in total and LDL-C levels with 
age, especially after the seventh decade [20, 21]. 
Although effectiveness of statins in elderly patients 
is demonstrated with published data, it is well 
known that a large number of patients do not re-
ceive this treatment at both discharge or at follow-
up periods [20–22]. In the EURIKA study, the rate 
of dyslipidemia in Europe was 57.7% whereas in 
Turkey it was significantly lower (34.5%) and had 
the lowest rates of all countries. Though, 30.4% 
of dyslipidemic patients treated in Turkey group 
reached target LDL-C levels, this was lower 
than the 41.2% observed in Europe [13]. In the 
EUROASPIRE III study lowering total cholesterol 
level rate was 51.7% in the Turkey group and 
48.9% in Europe [15]. Yet again, the use of statin 
rate after an index event was 65% in the Turkey 
group and 78.1% in Europe [16]. When compared 
to this study, both the rate of statin use and the 
number of patients that reached the target LDL-C 
levels were significantly lower than in this study. 
This could be explained by avoiding optimal drug 
use in the elderly by doctors due to polypharmacy, 
drug interactions and side effects. Also, in some 
patients the LDL-C level over 70 mg/dL might have 
reduced ≥ 50% from baseline, but if the baseline 
LDL-C level is not known it might have affected 
the number of patients reaching the target level 
proposed by ESC guidelines. 
Diabetes is among the most important cardio-
vascular risk factors. In the EURIKA study, the 
rate of diabetes in the Turkey group was 31.4% 
and 24.4% in Europe [13]. In EUROASPIRE III 
study, the rate of diabetes in Turkish subjects was 
similar to all patients included (33.6% and 34.8%, 
respectively). In this study 34.7% of patients had 
diabetes, this result correlates with prior studies. 
Both in this study and in previous studies, an aver-
age of 1 in 3 patients with CHD or cardiovascular 
risk factors has DM. 
The continuity of treatment during both at the 
acute stage and long-term is vitally important in 
CHD [2, 8]. The EUROASPIRE II, III and Turkey 
group of EUROASPIRE III survey have reported 
that 85.9%, 90.5%, and 91.4% of patients respec-
tively received an anti-platelet drug, 62.9%, 79.8%, 
and 73.8% of patients respectively received a beta-
blocker, 38%, 70.9%, and 69% of patients respec-
tively received ACEIs after discharge. In this study 
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79.3% of patients received an anti-platelet drug, 
70.8% received a beta-blocker and 68.1% received 
ACEI/ARB. A less significant use of anti-platelet 
drugs may be due to concerns about bleeding in 
elderly patients. Despite the proven effectiveness 
of beta-blocker and ACEI/ARB in treatment, usage 
rate was slightly different than in published data. 
The use of PPI with anti-platelet drug therapy is 
recommended in patients with high risk of bleed-
ing and with the elderly. Approximately half of the 
present patients were not receiving PPI therapy. 
Refusing medication in the elderly, avoidance of 
polypharmacy and various concerns physicians may 
have caused not initiating this efficient treatment 
for this patient group.
Limitations of the study
The most important limitation of the present 
study is that there is no comparison group. For 
this reason the data was compared with previous 
studies in Turkey and multicentre studies including 
Turkish patients. Due to being a cross-sectional 
study, some baseline laboratory values were not 
known and the discharge treatment is another 
limitation. When baseline laboratory values were 
not known for LDL-C  level of reduction could not 
be assessed. The patients were elderly and may 
have provided incomplete information. 
Conclusions
In conclusion, according to available literature 
this is the first study to evaluate the lifestyle, 
management of risk factors and medical treatment 
for secondary prevention among elderly patients 
in Turkey. Elder Turk study has shown that many 
patients with CHD have high prevalence of modifi-
able risk factors and unhealthy lifestyle. In addi-
tion, many patients are not receiving therapeutic 
intervention and as a consequence most are not 
achieving the recommended goals. There is wide 
gap in implementation of evidence-based medicine 
in practice. 
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